ESMO 2025: Highlights and analysis

PRAME-targeted TCR therapy shows high response rates in metastatic uveal melanoma

Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant metastasis-free survival

IO102-IO103 cancer vaccine plus pembrolizumab demonstrates PFS benefit in advanced melanoma

MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection

Memorial Cancer Institute's Best of ASCO® 2025

The hidden biology of addiction and cancer

Encorafenib/binimetinib/nivolumab combo improves PFS in BRAF-mutant melanoma brain metastases

Enhanced pathologic response with neoadjuvant pembrolizumab plus vidutolimod in high-risk resectable melanoma

Cemiplimab reduces disease recurrence as adjuvant therapy for cutaneous squamous cell carcinoma

Nivolumab/ipilimumab followed by BRAF/MEK inhibitors preferred sequence for BRAF-positive advanced melanoma

EGFR shows to be a promising therapeutic target in NF1 mutant melanoma